SUVRETTA CAPITAL MANAGEMENT, LLC
13F Reported Value
ⓘ$3.9B
incl. option notional
Equity Holdings
ⓘ$3.7B
Option Notional
ⓘ$227.6M
$227.6M puts / $0 calls
Holdings
89
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
SUVRETTA CAPITAL MANAGEMENT, LLC disclosed 89 positions worth $3.9B in its Form 13F-HR for Q1 2026 — $3.7B in common stock plus $227.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ARQT (Arcutis Biotherapeutics, Inc.) at 7.9% of the equity portfolio, followed by $MANE and $SPY. During the quarter the fund opened 15 new positions and exited 19 — including a new stake in $MANE. The portfolio is most concentrated in Healthcare (65.8% of disclosed assets). All figures are sourced directly from SUVRETTA CAPITAL MANAGEMENT, LLC’s Form 13F-HR filing with the SEC under CIK 1569064.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 41.2#1,908
Quality
$290.4M12,327,000 sh - —
Quality
$263.3M4,168,970 sh - —
Quality
$227.6M350,000 sh - —
Quality
$143.8M1,153,496 sh - 63.9
Quality
$141.5M3,518,471 sh - 44.2
Quality
$137.1M7,581,029 sh - —
Quality
$123.0M11,548,351 sh - —
Quality
$116.1M3,818,600 sh - —
Quality
$110.1M11,190,129 sh - 12.0
Quality
$108.7M5,030,993 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Arcutis Biotherapeutics, Inc.$ARQT | 41.2#1,908 | $290.4M | 12,327,000 |
 Veradermics, Inc$MANE | — | $263.3M | 4,168,970 |
 SPDR S&P 500 ETF TRUST$SPYPUT | — | $227.6M | 350,000 |
 PALVELLA THERAPEUTICS, INC.$PVLA | — | $143.8M | 1,153,496 |
 Apellis Pharmaceuticals, Inc.$APLS | 63.9 | $141.5M | 3,518,471 |
 Legend Biotech Corp$LEGN | 44.2 | $137.1M | 7,581,029 |
 Benitec Biopharma Inc.$BNTC | — | $123.0M | 11,548,351 |
 CAPRICOR THERAPEUTICS, INC.$CAPR | — | $116.1M | 3,818,600 |
 Immatics N.V.$IMTX | — | $110.1M | 11,190,129 |
 Arcus Biosciences, Inc.$RCUS | 12.0 | $108.7M | 5,030,993 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SUVRETTA CAPITAL MANAGEMENT, LLC's 89 positions.
Showing top 10 of 89 holdings.
Sector Allocation
Healthcare
$2.4B
Technology
$573.0M
Consumer Discretionary
$384.6M
Financials
$161.5M
Materials
$49.4M
Consumer Staples
$38.6M
Other
$33.2M
Communication Services
$14.3M
Full Holdings — SUVRETTA CAPITAL MANAGEMENT, LLC (Q1 2026)
All 89 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ARQT | Arcutis Biotherapeutics, Inc. | $290.4M | 7.9% | +3% | 41.2 |
| 2 | $MANE | Veradermics, Inc | $263.3M | 7.1% | NEW | — |
| 3 | $SPYPUT | SPDR S&P 500 ETF TRUST | $227.6M | — | -56% | — |
| 4 | $PVLA | PALVELLA THERAPEUTICS, INC. | $143.8M | 3.9% | +29% | — |
| 5 | $APLS | Apellis Pharmaceuticals, Inc. | $141.5M | 3.8% | -15% | 63.9 |
| 6 | $LEGN | Legend Biotech Corp | $137.1M | 3.7% | +15% | 44.2 |
| 7 | $BNTC | Benitec Biopharma Inc. | $123.0M | 3.3% | +0% | — |
| 8 | $CAPR | CAPRICOR THERAPEUTICS, INC. | $116.1M | 3.1% | +114% | — |
| 9 | $IMTX | Immatics N.V. | $110.1M | 3.0% | +0% | — |
| 10 | $RCUS | Arcus Biosciences, Inc. | $108.7M | 3.0% | -3% | 12 |
| 11 |  $EYPT | EyePoint, Inc. | $106.9M | 2.9% | +6% | 10.3 |
| 12 |  $AVBP | ArriVent BioPharma, Inc. | $101.5M | 2.8% | +7% | — |
| 13 |  $TSM | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD | $100.9M | 2.7% | +10% | — |
| 14 |  $NVDA | NVIDIA CORP | $100.2M | 2.7% | +8% | 90.2 |
| 15 |  $META | Meta Platforms, Inc. | $97.1M | 2.6% | +0% | 80.9 |
| 16 |  $KALV | KalVista Pharmaceuticals, Inc. | $96.0M | 2.6% | +0% | 25.9 |
| 17 |  $GE | GENERAL ELECTRIC CO | $88.0M | 2.4% | +0% | 74.8 |
| 18 |  $BHVN | Biohaven Ltd. | $87.0M | 2.4% | +0% | — |
| 19 |  $SYY | SYSCO CORP | $82.7M | 2.2% | +7% | 58.4 |
| 20 |  $MGM | MGM Resorts International | $79.9M | 2.2% | +80% | 48 |
| 21 |  $CMPX | Compass Therapeutics, Inc. | $75.7M | 2.0% | +1% | — |
| 22 |  $HD | HOME DEPOT, INC. | $72.9M | 2.0% | -8% | 69.2 |
| 23 |  $KURA | Kura Oncology, Inc. | $69.7M | 1.9% | +0% | 9.1 |
| 24 |  $GLUE | Monte Rosa Therapeutics, Inc. | $69.5M | 1.9% | +26% | 18.1 |
| 25 |  $BAC | BANK OF AMERICA CORP /DE/ | $63.1M | 1.7% | -15% | 68.4 |
| 26 |  $ERAS | Erasca, Inc. | $55.6M | 1.5% | -76% | — |
| 27 |  $COF | CAPITAL ONE FINANCIAL CORP | $55.2M | 1.5% | +76% | 71 |
| 28 |  $ZURA | Zura Bio Ltd | $53.9M | 1.5% | +63% | — |
| 29 |  $AMZN | AMAZON COM INC | $52.9M | 1.4% | -37% | 74.6 |
| 30 |  $AMD | ADVANCED MICRO DEVICES INC | $52.3M | 1.4% | -34% | 78.8 |
| 31 |  $FULC | Fulcrum Therapeutics, Inc. | $50.3M | 1.4% | +0% | — |
| 32 |  $VMC | Vulcan Materials CO | $49.4M | 1.3% | NEW | 66.6 |
| 33 |  $FERG | Ferguson Enterprises Inc. /DE/ | $49.4M | 1.3% | +33% | 58.9 |
| 34 |  $APO | Apollo Global Management, Inc. | $43.2M | 1.2% | -29% | 55.7 |
| 35 |  $MLYS | Mineralys Therapeutics, Inc. | $41.7M | 1.1% | +0% | — |
| 36 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $37.9M | 1.0% | NEW | 26.5 |
| 37 |  $CTNM | Contineum Therapeutics, Inc. | $37.1M | 1.0% | +0% | — |
| 38 |  $USFD | US Foods Holding Corp. | $36.5M | 1.0% | NEW | 60.6 |
| 39 |  $PFGC | Performance Food Group Co | $33.1M | 0.9% | NEW | 53.1 |
| 40 |  $REPL | Replimune Group, Inc. | $32.3M | 0.9% | NEW | — |
| 41 | — | ADVISORSHARES TR | $32.1M | 0.9% | +4% | — |
| 42 |  $AURA | Aura Biosciences, Inc. | $29.3M | 0.8% | +0% | — |
| 43 |  $UNH | UNITEDHEALTH GROUP INC | $27.2M | 0.7% | -10% | 66.8 |
| 44 |  $PROK | PROKIDNEY CORP. | $22.1M | 0.6% | +0% | 21.3 |
| 45 |  $LTH | Life Time Group Holdings, Inc. | $13.7M | 0.4% | NEW | 67.8 |
| 46 |  $WHWK | Whitehawk Therapeutics, Inc. | $12.8M | 0.3% | +0% | 9.6 |
| 47 |  $ABEO | ABEONA THERAPEUTICS INC. | $12.0M | 0.3% | +0% | 44.3 |
| 48 |  $WING | Wingstop Inc. | $9.2M | 0.3% | NEW | 75.1 |
| 49 |  $MOLN | MOLECULAR PARTNERS AG | $8.8M | 0.2% | +0% | — |
| 50 |  $BSX | BOSTON SCIENTIFIC CORP | $7.8M | 0.2% | -65% | 79.9 |
| 51 |  $LXEO | Lexeo Therapeutics, Inc. | $7.2M | 0.2% | +0% | — |
| 52 |  $COHR | COHERENT CORP. | $7.1M | 0.2% | -78% | 64 |
| 53 |  $IFRX | InflaRx N.V. | $7.1M | 0.2% | +0% | — |
| 54 |  $DHR | DANAHER CORP /DE/ | $6.9M | 0.2% | -85% | 63.9 |
| 55 |  $ABT | ABBOTT LABORATORIES | $6.9M | 0.2% | +31% | 67 |
| 56 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $6.6M | 0.2% | +0% | 63.7 |
| 57 |  $MDT | Medtronic plc | $6.3M | 0.2% | +188% | — |
| 58 |  $JNJ | JOHNSON & JOHNSON | $5.7M | 0.2% | -76% | 72.8 |
| 59 |  $KZR | Kezar Life Sciences, Inc. | $5.3M | 0.1% | +0% | — |
| 60 |  $ISRG | INTUITIVE SURGICAL INC | $5.2M | 0.1% | +117% | 81.4 |
| 61 |  $AVR | Anteris Technologies Global Corp. | $4.7M | 0.1% | NEW | — |
| 62 |  $COR | Cencora, Inc. | $3.9M | 0.1% | +0% | 59.6 |
| 63 |  $MSLE | Satellos Bioscience Inc. | $2.7M | 0.1% | NEW | — |
| 64 |  $MTD | METTLER TOLEDO INTERNATIONAL INC/ | $2.5M | 0.1% | +0% | 68.8 |
| 65 |  $NTRA | Natera, Inc. | $2.0M | 0.1% | +0% | 46.4 |
| 66 |  $DXCM | DEXCOM INC | $2.0M | 0.1% | +0% | 77.9 |
| 67 |  $SYK | STRYKER CORP | $1.9M | 0.1% | +0% | 69.8 |
| 68 |  $TSLA | Tesla, Inc. | $1.9M | 0.1% | -94% | 50.1 |
| 69 |  $TLN | Talen Energy Corp | $1.9M | 0.1% | NEW | 66.5 |
| 70 |  $MDLN | Medline Inc. | $1.9M | 0.1% | +0% | — |
| 71 |  $MSFT | MICROSOFT CORP | $1.8M | 0.1% | -97% | 83.7 |
| 72 |  $MCK | MCKESSON CORP | $1.6M | 0.0% | +0% | 63.7 |
| 73 |  $HCA | HCA Healthcare, Inc. | $1.5M | 0.0% | +0% | 70.5 |
| 74 |  $EW | Edwards Lifesciences Corp | $1.5M | 0.0% | +68% | 67.6 |
| 75 |  $IQV | IQVIA HOLDINGS INC. | $1.2M | 0.0% | +0% | 59.7 |
| 76 |  $GWW | W.W. GRAINGER, INC. | $1.1M | 0.0% | NEW | 69.5 |
| 77 | — | SENSEI BIOTHERAPEUTICS INC | $1.1M | 0.0% | NEW | — |
| 78 |  $WAT | WATERS CORP /DE/ | $960,405 | 0.0% | +2% | 69.9 |
| 79 |  $VST | Vistra Corp. | $901,980 | 0.0% | NEW | 62.9 |
| 80 |  $IONS | IONIS PHARMACEUTICALS INC | $810,972 | 0.0% | +0% | 37.1 |
| 81 |  $A | AGILENT TECHNOLOGIES, INC. | $568,760 | 0.0% | +0% | 64.6 |
| 82 |  $RMD | RESMED INC | $536,507 | 0.0% | +0% | 79.8 |
| 83 |  $SPOT | Spotify Technology S.A. | $533,401 | 0.0% | NEW | — |
| 84 |  $VLTO | Veralto Corp | $484,100 | 0.0% | +0% | 74.4 |
| 85 |  $RBLX | Roblox Corp | $476,235 | 0.0% | NEW | 53.7 |
| 86 |  $SRPT | Sarepta Therapeutics, Inc. | $389,243 | 0.0% | +0% | 41.6 |
| 87 |  $STE | STERIS plc | $338,329 | 0.0% | +0% | — |
| 88 |  $VRDN | Viridian Therapeutics, Inc.\DE | $326,652 | 0.0% | +0% | 30.5 |
| 89 |  $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $294,769 | 0.0% | +0% | 64.9 |
New Positions (15)
$MANE Veradermics, Inc$263.3M$VMC Vulcan Materials CO$49.4M$CRNX Crinetics Pharmaceuticals, Inc.$37.9M$USFD US Foods Holding Corp.$36.5M$PFGC Performance Food Group Co$33.1M$LTH Life Time Group Holdings, Inc.$13.7M$WING Wingstop Inc.$9.2M$AVR Anteris Technologies Global Corp.$4.7M$MSLE Satellos Bioscience Inc.$2.7M$TLN Talen Energy Corp$1.9M$GWW W.W. GRAINGER, INC.$1.1M$VST Vistra Corp.$901,980$SPOT Spotify Technology S.A.$533,401$RBLX Roblox Corp$476,235Exited Positions (19)
$KO COCA COLA CO
$HIMSPUT Hims & Hers Health, Inc.
$NOW ServiceNow, Inc.
$CRM Salesforce, Inc.
$RARE Ultragenyx Pharmaceutical Inc.
$ORCL ORACLE CORP
$QURE uniQure N.V.
$CMG CHIPOTLE MEXICAN GRILL INC
$TNGX Tango Therapeutics, Inc.
$BIIB BIOGEN INC.
$DKS DICK'S SPORTING GOODS, INC.
$GS GOLDMAN SACHS GROUP INC
$INSM INSMED Inc
$RCKT ROCKET PHARMACEUTICALS, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SUVRETTA CAPITAL MANAGEMENT, LLC including:
Track SUVRETTA CAPITAL MANAGEMENT, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SUVRETTA CAPITAL MANAGEMENT, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SUVRETTA CAPITAL MANAGEMENT, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For SUVRETTA CAPITAL MANAGEMENT, LLC (SEC CIK: 1569064), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SUVRETTA CAPITAL MANAGEMENT, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.